For Inherent Anticipation, How Many Is Too Many? - Patent

The US Court of Appeals for the Federal Circuit affirmed a Patent Trial & Appeal Board (Board) decision that prior art disclosing a class of 957 salts could not inherently anticipate claims...

Related Keywords

Mylan Pharms ,Us Court ,Merck Sharp Dohme Corp ,Federal Circuit ,Patent Trial ,Appeal Board ,Dohme Corp ,Patents Appeals ,Mondaq ,A7 103c 1 ,Ntedation ,Nherent Anticipation ,Ylan Pharms Incv Merck Sharp Amp Dohme Corp ,Obviousness ,Atent Trial Amp Appeal Board ,Erson Of Ordinary Skill In The Art Posa ,Intellectual Property ,Patent , ,